Literature DB >> 11764350

Acetabular reconstruction with bone impaction grafting and a cemented cup: 20 years' experience.

B W Schreurs1, T J Slooff, J W Gardeniers, P Buma.   

Abstract

Acetabular bone stock loss compromises the outcome in primary and revision total hip arthroplasty. In 1979, a biologic method was introduced with tightly impacted cancellous allografts in combination with a cemented polyethylene cup for acetabular reconstruction. With this technique, it is possible to replace the loss of bone and to repair normal hip mechanics and hip function with a standard implant. Based on the authors' 20 years experience, a review of the long-term data is presented in primary total hip arthroplasty with preexisting acetabular bone stock loss, primary total hip arthroplasty in rheumatoid arthritis, patients who had bone impaction when younger than 50 years, and in acetabular revisions. The survival rate with revision of the cup for aseptic loosening as the end point was 94% at 10 to 17 years, 90% at 10 to 18 years, 91% at 10 to 17 years, and 92% at 10 to 15 years. From biopsy specimens from humans and histologic data in animal experiments the incorporation of these impacted bone chips was proven. The acetabular bone impaction technique using large morselized bone chips (range, 0.7-1 cm) and a cemented cup is a reliable technique with favorable long-term outcome.

Entities:  

Mesh:

Year:  2001        PMID: 11764350     DOI: 10.1097/00003086-200112000-00023

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  35 in total

1.  Large acetabular defects can be managed with cementless revision components.

Authors:  E Scott Paxton; James A Keeney; William J Maloney; John C Clohisy
Journal:  Clin Orthop Relat Res       Date:  2011-02       Impact factor: 4.176

2.  High failure rate with the GAP II ring and impacted allograft bone in severe acetabular defects.

Authors:  Martin A Buttaro; Diego Muñoz de la Rosa; Fernando Comba; Francisco Piccaluga
Journal:  Clin Orthop Relat Res       Date:  2012-11       Impact factor: 4.176

3.  The fate of grafting acetabular defects during revision total hip arthroplasty.

Authors:  Nathan A Mall; Ryan M Nunley; Kirk E Smith; William J Maloney; John C Clohisy; Robert L Barrack
Journal:  Clin Orthop Relat Res       Date:  2010-12       Impact factor: 4.176

4.  Revision hip arthroplasty using impacted cancellous bone and cement: a long-term follow-up study.

Authors:  Gowthaman Arumugam; Shashi Kumar Nanjayan; Conal Quah; Philip Wraighte; Peter Howard
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-09-23

5.  Acetabular revision with freeze-dried irradiated and chemically treated allograft: a minimum 5-year follow-up of 17 cases.

Authors:  Bernardo Vargas; Jacques Caton
Journal:  Int Orthop       Date:  2007-09-09       Impact factor: 3.075

6.  Acetabular revision surgery with impacted bone allografts and cemented cups in patients younger than 55 years.

Authors:  Fernando Comba; Martín Buttaro; Rodolfo Pusso; Francisco Piccaluga
Journal:  Int Orthop       Date:  2008-02-09       Impact factor: 3.075

7.  A review of the treatment of pelvic discontinuity.

Authors:  M Villanueva; A Rios-Luna; J Pereiro De Lamo; H Fahandez-Saddi; M P G Böstrom
Journal:  HSS J       Date:  2008-07-15

8.  Good results with cemented total hip arthroplasty in patients between 40 and 50 years of age.

Authors:  Daniël C J de Kam; Jean W M Gardeniers; René P H Veth; B Willem Schreurs
Journal:  Acta Orthop       Date:  2010-04       Impact factor: 3.717

9.  Impregnation of bone chips with antibiotics and storage of antibiotics at different temperatures: an in vitro study.

Authors:  Nina M C Mathijssen; Pieter L C Petit; Peter Pilot; B Wim Schreurs; Pieter Buma; Rolf M Bloem
Journal:  BMC Musculoskelet Disord       Date:  2010-05-25       Impact factor: 2.362

10.  Bone healing of severe acetabular defects after revision arthroplasty.

Authors:  Gösta Ullmark; Jens Sörensen; Olle Nilsson
Journal:  Acta Orthop       Date:  2009-04       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.